Published in Cancer Weekly, July 6th, 2004
The results were published in the Proceedings of the 2004 American Society for Clinical Oncology (ASCO) Annual Meeting. Novacea has licensed from KuDOS the North American rights to develop and commercialize AQ4N and plans to initiate its clinical development program shortly. KuDOS is developing AQ4N in Europe and other markets outside North America.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.